Issues in blinded sample size re-estimation
- 1 January 1997
- journal article
- research article
- Published by Taylor & Francis in Communications in Statistics - Simulation and Computation
- Vol. 26 (3) , 1229-1239
- https://doi.org/10.1080/03610919708813436
Abstract
The utility of blinded sample size re-estimation for clinical trials depends on the ability to estimate variability without providing information about the true treatment difference, and on some reasonable assurance that the method is not likely to cause the sample size to be increased when the treatment effect is better than anticipated. We show that violations of these properties are unlikely to occur in practice.Keywords
This publication has 3 references indexed in Scilit:
- Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. CPMP working party on efficacy of medicinal products note for guidance III/3630/92‐ENStatistics in Medicine, 1995
- Interim analyses for monitoring clinical trials that do not materially affect the type I error rateStatistics in Medicine, 1992
- Sample size re-estimation without unblinding for normally distributed outcomes with unknown varianceCommunications in Statistics - Theory and Methods, 1992